Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes

Korean Journal of Internal Medicine

Volumn 24, Issue 3, 2009, Pages 227-232

  Kim, Mee Kyoung ^a   Ko, Seung Hyun ^a   Baek, Ki Hyun ^a   Ahn, Yu Bae ^a   Yoon, Kun Ho ^a   Kang, Moo Il ^a   Lee, Kwang Woo ^a   Song, Ki Ho ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Diabetic nephropathies; Renal insufficiency; Rosiglitazone

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; INSULIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ADULT; AGED; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 70449707755     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.3.227     Document Type: Article

References (23)

1. Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-1334.
2. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002;51:403-408. (Pubitemid 34406552)
3. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-2139. (Pubitemid 28549163)
4. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12. (Pubitemid 36163426)
5. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-2211. (Pubitemid 40911285)
6. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-2055.
7. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367-1373. (Pubitemid 350126770)
8. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endorinol Metab 2004;89:6068-6076. (Pubitemid 39628416)
9. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-174. (Pubitemid 40467663)
10. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 2005;68:285-292. (Pubitemid 43181387)
11. Jin HM, Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 2007;30:203-211. (Pubitemid 47076217)
12. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006;29(Suppl):S4-S42.
13. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277. (Pubitemid 37430080)
14. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004;27:195-200. (Pubitemid 38196732)
15. New JP, Middleton RJ, Klebe B, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007;24:364-369. (Pubitemid 46452394)
16. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002;17:1909-1913.
17. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10- year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999;22:743-751. (Pubitemid 29220773)
18. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147. (Pubitemid 38129105)
19. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70:1223-1233.
20. Sakharova OV, Taal MW, Brenner BM. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 2001;10:727-738. (Pubitemid 33043665)
21. Perico N, Remuzzi G. Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int 2007;72:1419-1421. (Pubitemid 350197959)
22. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007;292:F1141-F1150. (Pubitemid 46578056)
23. Chudleigh RA, Dunseath G, Evans W, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 2007;30:300-305.